Roundup Litigation: Understanding the $2 Billion Verdict Reduction and Current Status (November 2025)
In 2019, a California jury awarded a couple $2 billion in damages after they developed non-Hodgkin’s lymphoma (NHL) following years of Roundup use. This landmark verdict, Pilliod v. Monsanto, sent shockwaves through the agricultural and legal worlds. However, the initial award was later reduced to $87 million by the judge, highlighting a recurring theme in Roundup litigation: substantial initial verdicts often face reductions due to legal limitations on punitive damages.
Why the Reduction?
The judge in the Pilliod case, like others before and since, cited U.S. Supreme Court precedents that limit punitive damages to a reasonable ratio relative to compensatory damages. While the jury found Monsanto liable for negligence and failure to warn about Roundup’s cancer risks, the initial punitive damage amounts were deemed excessive under constitutional standards.
The Science Behind the Lawsuits
At the heart of the Roundup litigation lies the question of whether glyphosate, the active ingredient in Roundup, causes cancer. Plaintiffs in these cases, primarily those who have developed NHL, argue that exposure to Roundup significantly increased their risk of developing the disease.
- IARC Classification: In 2015, the International Agency for Research on Cancer (IARC), a part of the World Health Organization, classified glyphosate as “probably carcinogenic to humans”. This classification has been a cornerstone of the plaintiffs’ arguments.
- Studies Linking Glyphosate to NHL: Meta-analyses and other studies have shown a correlation between glyphosate exposure and an increased risk of NHL. For example, a 2019 review by University of Washington scientists found that individuals with high glyphosate exposure had a 41% increased risk of NHL.
- Conflicting Scientific Opinions: It’s important to note that regulatory agencies like the U.S. Environmental Protection Agency (EPA) have maintained that glyphosate is “not likely” to cause cancer in humans. This discrepancy between different scientific bodies has fueled the legal battles.
Where Does the Roundup Litigation Stand in November 2025?
The Roundup litigation is far from over. Here’s a snapshot of the current situation:
- Settlements: As of May 2025, Bayer (which acquired Monsanto in 2018) has reached settlement agreements in nearly 100,000 Roundup lawsuits, paying approximately $11 billion.
- Pending Cases: Despite these settlements, an estimated 61,000 active Roundup lawsuits remain pending. The majority of these cases are now in state courts across the country, though more than 4,000 remain consolidated in the federal MDL in California.
- Recent Verdicts: Recent jury verdicts have continued to be a mix of wins and losses for both sides. Some notable examples include:
- A Missouri court upheld a jury award of $611 million to three plaintiffs who developed NHL after Roundup exposure.
- The Pennsylvania Superior Court affirmed a $175 million verdict awarded to Ernest Caranci, who developed non-Hodgkin’s lymphoma after decades of using Roundup.
- In March 2025, a Georgia jury awarded nearly $2.1 billion to a man who developed non-Hodgkin lymphoma after years of Roundup usage.
- Appeals: Bayer continues to appeal unfavorable verdicts, often arguing that the science does not support a causal link between Roundup and cancer and that damage awards are excessive.
- Potential Bankruptcy: There have been reports that Bayer may consider filing for bankruptcy for its Monsanto unit if it is unsuccessful in settling Roundup cases.
- Future Lawsuits: New Roundup lawsuits continue to be filed regularly, indicating that the litigation will likely continue for years to come.
What Types of Cancers are Linked to Roundup?
While non-Hodgkin’s lymphoma is the most commonly cited cancer in Roundup lawsuits, other cancers have also been linked to glyphosate exposure, including:
- Acute Myeloid Leukemia
- Large B-Cell Lymphoma
Factors Affecting Settlement Amounts
The average settlement amount in Roundup lawsuits is estimated to be around $160,000, but actual payouts can vary significantly based on several factors:
- Severity of the Illness: More severe cases of cancer, particularly those with aggressive forms of NHL, tend to result in higher settlements.
- Extent of Exposure: The duration and intensity of Roundup exposure are also critical factors. Individuals with long-term, heavy exposure are more likely to receive larger settlements.
- Strength of Evidence: The strength of the scientific evidence linking the plaintiff’s cancer to Roundup exposure is crucial.
- Age and General Health: The plaintiff’s age and overall health can also influence settlement amounts.
- Legal Representation: Having experienced and knowledgeable attorneys can significantly impact the outcome of a Roundup case.
The Future of Roundup
Bayer is taking steps to manage the ongoing litigation and mitigate future risks. These include:
- Reformulating Roundup: Bayer is working to replace glyphosate with other ingredients in Roundup products for the consumer market.
- Seeking Legal Protections: Bayer has been lobbying for legislation that would shield the company from future Roundup lawsuits.
- Continuing to Defend Roundup’s Safety: Bayer maintains that Roundup is safe when used as directed and that the scientific evidence does not support a causal link between glyphosate and cancer.
Have You Been Affected by Roundup?
If you or a loved one has been diagnosed with non-Hodgkin’s lymphoma or another type of cancer after exposure to Roundup, it’s essential to seek legal advice. An experienced attorney can evaluate your case, explain your legal options, and help you pursue compensation for your injuries.